Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.

ABSTRACT:

Background

A better understanding of drivers of treatment costs may help identify effective cost containment strategies and prioritize resources. We aimed to develop a method for estimating inpatient costs for pediatric patients with acute myeloid leukemia (AML) enrolled on NCI-funded Phase III trials, compare costs between AAML0531 treatment arms (standard chemotherapy ± gemtuzumab ozogamicin (GMTZ)), and evaluate primary drivers of costs for newly diagnosed pediatric AML.

Procedure

Patients from the AAML0531 trial were matched on hospital, sex, and dates of birth and diagnosis to the Pediatric Health Information Systems (PHIS) database to obtain daily billing data. Inpatient treatment costs were calculated as adjusted charges multiplied by hospital-specific cost-to-charge

SUBMITTER: Getz KD 

PROVIDER: S-EPMC4546551 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature